Ovid Therapeutics Inc. has provided an update on its strategic focus and ongoing developments in their corporate presentation. The company is concentrating on foundational biological targets related to neuronal hyperexcitability, with an emphasis on precision small molecules and differentiated mechanisms of action. Ovid reports a cash balance of $43 million, anticipated to support operations into the second half of 2026. The company highlighted its differentiated pipeline, including OV329, a next-generation GABA-aminotransferase inhibitor aimed at drug-resistant epilepsies. The Phase 1 safety and biomarker results for OV329 are expected in Q3 2025, with Phase 2 initiation planned for Q1 2026. Other pipeline developments include OV350, a KCC2 direct activator, and OV4041 for generalized anxiety disorder or Rett syndrome. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.